The use of botulinum toxin in benign prostatic hyperplasia

Neurourology and Urodynamics

Volumn 31, Issue 1, 2012, Pages 86-92

  Marchal, Cristobal ^a   Perez, Juan E ^a   Herrera, Bernardo ^a   MacHuca, Francisco J ^a   Redondo, Maximino ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

benign prostatic hyperplasia; botulinum toxin; LUTS

Indexed keywords

ABOBOT A; BOTULINUM TOXIN A; ONABOT A; PLACEBO; UNCLASSIFIED DRUG;

CANCER SIZE; DRUG EFFICACY; FOLLOW UP; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; META ANALYSIS; NONHUMAN; ORGAN SIZE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANIMALS; BOTULINUM TOXINS, TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INJECTIONS; LOWER URINARY TRACT SYMPTOMS; MALE; MODELS, ANIMAL; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME;

EID: 84856220932     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.21142     Document Type: Review

References (46)

1. Ventura S, Penneafather JN, Mitchelson F,. Cholinegic innervation and function on the prostate gland. Pharmacol Ther 2002; 94: 93-112.
2. Marinese D, Patel R, EWalden PD,. Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice. Prostate 2003; 54: 230-7.
3. Ille CP, Chancellor MB,. Perspective of botox for treatment of male lower urinary tract symptoms. Curr Opin Urol 2010; 25: 10-20.
4. Coffey DS, Walsh PC,. Clinical and experimental studies of benign prostate hyperplasia. Urol Clin North Am 1990; 17: 461-75.
5. Smith CP, Franks ME, Mcneil BK, et al. Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 2003; 169: 1896-900.
6. Jones OM, Moore JA, Branding AF, et al. Botulinum toxin injection inhibits myogenic tone and sympathetic nerve function in the porcine internal anal sphincter. Colorectal Dis 2003; 5: 552-7.
7. Long L, Hang AT, Yang A, et al. Effects of botulinum toxin A on the contractile function of dog prostate. Eur Urol 2007; 52: 582-9.
8. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12.
9. Higgins JPT, Green S,. Assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of Interventions (Chapter 8) 2008 Version 5.0.0 (updated February 2008). The Cochrane Collaboration.
10. Little J, Higgins JP, Ioannidis JP, et al. Strengthening the Reporting of Genetic Association studies (STREGA) - An extension of the STROBE statement. Eur J Clin Invest 2009; 39: 247-66.
11. Chuang YC, Huang CC, Ling HJ, et al. Intraprostatic injection of botulinum toxin typer A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urol 2006; 6: 12.
12. Park DS, Cho TW, Lee YK, et al. Evaluation of short-term clinical effects presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia Yonsei Med J 2006; 47: 706-14.
13. Carwford D, Donnelll R, Hirst K, et al. 12-Week results of a phase I trial of 100 and 300 units of botulinum neurotoxin type A (BONT-A) for the management of benign prostatic hyperplasia (BPH). J Urol 2009; 181: 649.
14. Kuo HC, Liu HT,. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scand J Urol Nephrol 2009; 43: 206-11.
15. Mirkin YB, Bedredtdinova D,. Comparative study of efficiency and safety of intraprostatic injections of botulinum toxin and polidocanol in men with BPH and LUTS. Eur Urol 2010; 9: 312.
16. Chuang YC, Chiang PH, Huang CC, et al. Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostate. Urology 2005; 66: 775-9.
17. Larson TR, Scottsdalle AZ, Huidobro C, et al. Intraprostatic injection of botulinum toxin in the treatment of symptomatic LUTS, including sequential MRIs for accurate changes in size of the prostate. J Urol 2005; 173: 764.
18. Maria G, Brisinda G, Civello IM, et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: Results of a randomized, placebo-controlled study. Urology 2003; 62: 259-64.
19. Brisinda G, Cadeddou F, Vanella S, et al. Relief of botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: Early and long-term results. Urology 2009; 73: 90-4.
20. Nikoobakht M, Daneshpajooh A, Amadi A, et al. Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: Initial experience with Dysport. Scand J Urol Nephrol 2010; 44: 151-7.
21. Silva J, Silva C, Saraiva I, et al. Intraprostatic botulinum toxin type A injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol 2008; 53: 153-9.
22. Silva J, Pinto R, Carvalho T, et al. Intraprostatic botulinum toxin type A injection in patients with benign prostatic enlargement: Duration of the effect of a single treatment. BMC Urol 2009; 9: 1-6.
23. Chuang YC, Chiang PH, Yoshimura N, et al. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 2006; 98: 1033-7.
24. De Kort LM, Rosier P, Kok E, et al. Clinical urodinamics and histologic results of intraprostatic injections with botulinum toxin type A for lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol 2009; 181: 703.
25. Sreedar R, Chawle A, Thomas J,. Botulinum toxin in high risk BPH patients in retention. Indian J Urol 2008; 24: 276.
26. Gorgal TG, Silva JA, Pinto RA, et al. Intraprostatic injection of botulinum toxin type A causes a long lasting improvement in LUTS and urinary flow in patients with benign prostatic enlargement refractory to standard medical therapy. Eur Urol 2010; 9: 312.
27. Chuang YC, Huang CC, Kang HY, et al. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol 2006; 175: 1158-63.
28. Doggweiler R, Zerman DH, Ishigooka M, et al. Botox induced prostatic involution. Prostate 1998; 37: 44-50.
29. Chuang YC, Yoshimura N, Huang CC, et al. Intraprostatic capsaicin injection as a novel model for nonbacterial prostatitis and effects of botulinum toxin A. Eur Urol 2007; 51: 1119-27.
30. Chuang Y, Yoshimura N, Huang C, et al. Intraprostatic botulinum toxin injection inhibits cyclooxigenase-2 expression and suppresses prostatic pain on capsaicin induces prostatitis model in rats. J Urol 2008; 180: 742-8.
31. Xu Y, Yu X, Ye Z, et al. Effects of intraprostatic injection of botulinum toxin A (BTX-A) of benign prostate hyperplasia. Zhonghua Nan Ke Xue 2010; 16: 905-10.
32. Silva J, Pinto R, Carvalho T, et al. Mechanism of prostate atrophy after glandular botulinum neurotoxin type a injection: An experimental study in the rat. Eur Urol 2009; 56: 134-40.
33. Gorgal T, Charrua A, Silva JF, et al. Expression of apoptosis-regulating genes in the rat prostate after BONTA/A injection. Eur Urol Suppl 2010; 9: 209.
34. Jasinski M, Drewa T, Tyloch J, et al. Is botulinum toxintype A intraprostatic injection effective in patients with urinary retention? Eur Urol 2009; 10: 567-605.
35. Karsenty G, Roche J, Scarlata E, et al. Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo. Prostate 2009; 11: 1143-50.
36. McVary K, Crawford D, Donnel R, et al. MIST-2: Baseline PSA and total prostate volume predicts clinical response to intraprostatic injection of botulinum toxin for the treatment of LUTS. J Urol 2010; 183: 690.
37. Kuo HC,. Prostate botulinum A toxin injection - An alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005; 65: 670-4.
38. Agrawal SK, Agarwal MM, Singh SK,. Intraprostatic injection of botulinum toxin A: A promising treatment for patients with benign prostatic hyperplasia. Indian J Urol 2009; 25: 421-3.
39. Guercini F, Giannantoni A, Bard RL, et al. Intraprostatic botulin toxin injection in patients with severe benign prostatic hyperplasia: A multicenter feasibility study. J Urol 2005; 173: 376-7.
40. Kuo HC,. Therapeutic effects of botulinum toxin A on large benign prostatic hyperplasia with persistent lower urinary tract symptoms and suboptimal treatment outcome of combination medical therapy - Clinical and histological investigation of effects. J Urol 2007; 177: 609-10.
41. Silva JF, Pinto R, Botelho F, et al. Duration of the effects of a single intraprostatic injection of botulinum toxin type A in frail elderly patients with benign prostatic enlargement. J Urol 2009; 182: 650.
42. Nikoobakht MR, Ahmadi H, Daneshpajouh A, et al. Intraprostatic disport is a safe and efficacious treatment for benign prostatic hyperplasia. Eur Urol 2010; 9: 313.
43. Anglin I, Glassman D, Kyprianou N,. Induction of prostate apoptosis by alpha-1 adrenoreceptor antagonist: Mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis 2002; 5: 88-95.
44. Silva J, Pinto R, Carvalho T, et al. Intraprostatic botulinum toxin type A administration: Evaluation of the effects on sexual function. BJU Int 2010; DOI: 10.1111/j. 1464-410X.
45. Beylot C,. Different botulinum toxins and their specifications. Ann Dermatol Venérelo 2009; 136: S77-85.
46. Brisinda G, Albanese A, Cadeddu F, et al. Botulinum neurotoxin to treat chronic anal fissure: Results of a randomized 'botox vs. dysport' controlled trial. Aliment Pharmacol Ther 2004; 19: 695-701.